intravesical bcg+interferon-α-2b in prevention of recurrence in transitional cell carcinoma of urinary bladder
Clicks: 479
ID: 144442
2000
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
67.1
/100
479 views
356 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #3 of 39 articles by views in interventions
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Bladder malignancy is the 11th most common cancer in the world with more than 2,00,000 new cases diagnosed every year 90% of these are TCC, of which 75-80% are superficial in nature.
Our aim in this study was to find the efficacy, safety and cost effectiveness of a low dose intravesical imnumo-therapy with BCG (70 mg) + Interferon-α-2b in preven-tion of its recurrence and prolonging disease progression interval.
Between Jan. ′94 to Dec. ′98, 100 patients with super-ficial TCC (Ta, TI) of urinary bladder with or without Tis after transurethral resection of tumor underwent intra-vesical instillation of BCG (70 ing) + Interferon-α-2b (5-million IU) weekly for 8 weeks, fortnightly for 8 weeks, monthly . for 8 weeks . followed by maintenance dose at the end of 9th, 12th, 18th & 24th months with follow-up for 60 months.
Results: At the end of 60 months of follow-up 36 pa-tients (36%) showed complete response, 44 patients (44%) showed partial response, resulting in a total response rate of 80% while 20% progressed to higher stage & grade. Patients′ tolerance was good and adverse reaction was low 19%.
Conclusion: This study has shown that a low dose com-bined therapy with BCG and Interferon is not only safe, well tolerated, cost effective but also highly efficient in preventing recurrences in 36%, maintaining superficial nature of the disease in another 44% with a disease pro-gression free interval of 5 years in 80% of cases.
| Reference Key |
mohanty2000indianintravesical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Nayan K Mohanty;M N Mandal;A N Sinha;Alok K Jha |
| Journal | interventions |
| Year | 2000 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.